ArticleAmerican journal of respiratory and critical care medicine2018
Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial.
Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01504867 (LIPS-A), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LIPS-A: Lung Injury Prevention Study With Aspirin
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: A single-blind randomized controlled trial.Clinical and translational medicine · 2022Trial
- Trial
- High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Trial
- Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.Nature communications · 2026Article
- Targeted deletion of macrophage ferritin heavy chain protects from macrophage ferroptosis in acute respiratory distress syndrome.Research square · 2026Article
- Proresolving Lipid Mediators in the Respiratory System.Annual review of physiology · 2025Review
- Acetylsalicylic acid and dihydroartemisinin combined therapy on experimental malaria-associated acute lung injury: analysis of lung function and the inflammatory process.Malaria journal · 2024Article
- Neutrophil reduction attenuates the severity of lung injury in the early phase of pneumococcal pneumonia in mice.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Circulating cellular clusters are associated with thrombotic complications and clinical outcomes in COVID-19.iScience · 2023Article
- Article
- Impact of e-cigarette aerosol on primary human alveolar epithelial type 2 cells.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Platelets at the Crossroads of Pro-Inflammatory and Resolution Pathways during Inflammation.Cells · 2022Review
- Lipid-Derived Mediators are Pivotal to Leukocyte and Lung Cell Responses in Sepsis and ARDS.Cell biochemistry and biophysics · 2021Review
- Inflammation resolution circuits are uncoupled in acute sepsis and correlate with clinical severity.JCI insight · 2021Article
- Coagulation Dysfunction in Acute Respiratory Distress Syndrome and Its Potential Impact in Inflammatory Subphenotypes.Frontiers in medicine · 2021Review
- Article
- Novel Perspectives Regarding the Pathology, Inflammation, and Biomarkers of Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2020Review
- Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients.Thrombosis and haemostasis · 2020Article
- Plasma Levels of Proresolving and Prophlogistic Lipid Mediators: Association With Severity of Respiratory Failure and Mortality in Acute Respiratory Distress Syndrome.Critical care explorations · 2020Article
- Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations.American journal of respiratory and critical care medicine · 2020Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
rationaleAcute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies.
objectivesTo determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS.
methodsPatients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B MEASUREMENTS AND MAIN
resultsThirty-three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB
conclusionsBiomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk. Clinical trial registered with www.clinicaltrials.gov (NCT01504867).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.